Abstract
Among several types of DNA lesions, the DNA double strand breaks (DSBs) are one of the most deleterious and harmful. Mammalian cells mount a coordinated response to DSBs with the aim of appropriately repair the DNA damage. Indeed, failure of the DNA damage response (DDR) can lead to the development of cancer-prone genetic diseases. The identification and development of drugs targeting proteins involved in the DDR is even more investigated, as it gives the possibility to specifically target cancer cells. Indeed, the administration of DNA repair inhibitors could be combined with chemo- and radiotherapy, thus improving the eradication of tumor cells. Here, we provide an overview about DSBs damage response, focusing on the role of the DSBs repair mechanisms, of chromatin modifications, and of the cancer susceptibility gene BRCA1 which plays a multifunctional role in controlling genome integrity. Moreover, the most investigated DSBs enzyme inhibitors tested as potential therapeutic agents for anti-cancer therapy are reported.
Keywords: DNA damage response, DNA double strand breaks, DNA repair, cancer susceptibility, inhibitors of DNA repair, cancer therapy
Current Medicinal Chemistry
Title: Targeting the DNA Double Strand Breaks Repair for Cancer Therapy
Volume: 17 Issue: 19
Author(s): Francesca Gullotta, Elisabetta De Marinis, Paolo Ascenzi and Alessandra di Masi
Affiliation:
Keywords: DNA damage response, DNA double strand breaks, DNA repair, cancer susceptibility, inhibitors of DNA repair, cancer therapy
Abstract: Among several types of DNA lesions, the DNA double strand breaks (DSBs) are one of the most deleterious and harmful. Mammalian cells mount a coordinated response to DSBs with the aim of appropriately repair the DNA damage. Indeed, failure of the DNA damage response (DDR) can lead to the development of cancer-prone genetic diseases. The identification and development of drugs targeting proteins involved in the DDR is even more investigated, as it gives the possibility to specifically target cancer cells. Indeed, the administration of DNA repair inhibitors could be combined with chemo- and radiotherapy, thus improving the eradication of tumor cells. Here, we provide an overview about DSBs damage response, focusing on the role of the DSBs repair mechanisms, of chromatin modifications, and of the cancer susceptibility gene BRCA1 which plays a multifunctional role in controlling genome integrity. Moreover, the most investigated DSBs enzyme inhibitors tested as potential therapeutic agents for anti-cancer therapy are reported.
Export Options
About this article
Cite this article as:
Gullotta Francesca, De Marinis Elisabetta, Ascenzi Paolo and di Masi Alessandra, Targeting the DNA Double Strand Breaks Repair for Cancer Therapy, Current Medicinal Chemistry 2010; 17 (19) . https://dx.doi.org/10.2174/092986710791233698
DOI https://dx.doi.org/10.2174/092986710791233698 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
Current Cancer Drug Targets Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease
Current Vascular Pharmacology Editorial [ Hot Topic:New Frontiers in Female Reproduction and Fertility (Executive Guest Editor: Sandra Cecconi)]
Current Pharmaceutical Design HDL as a Target for Glycemic Control
Current Drug Targets The Many Faces of MTA3 Protein in Normal Development and Cancers
Current Protein & Peptide Science Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Incorporation of Selenocysteine into Proteins Using Peptide Ligation
Protein & Peptide Letters The Management of Metastatic Bone Disease with the Combination of Bisphosphonates and Radiotherapy: From Theory to Clinical Practice
Anti-Cancer Agents in Medicinal Chemistry Glucose-6-phosphate Dehydrogenase: a Biomarker and Potential Therapeutic Target for Cancer
Anti-Cancer Agents in Medicinal Chemistry Hydrophilic Carotenoid Amphiphiles: Methods of Synthesis and Biological Applications
Mini-Reviews in Medicinal Chemistry The Evaluation of Multivariate Adaptive Regression Splines for the Prediction of Antitumor Activity of Acridinone Derivatives
Medicinal Chemistry Editorial [Hot topic: QSAR and Complex Networks in Pharmaceutical Design, Microbiology, Parasitology, Toxicology, Cancer and Neurosciences (Executive Editor: Humberto Gonzalez-Diaz)]
Current Pharmaceutical Design Cullin-RING Ligases as Attractive Anti-cancer Targets
Current Pharmaceutical Design Reproductive Effects of Low-to-Moderate Medical Radiation Exposure
Current Medicinal Chemistry Computer Aided Drug Design: Success and Limitations
Current Pharmaceutical Design Preface:
Recent Patents on Nanomedicine Control of Melanoma Invasiveness by Anticollagenolytic Agents: A Reappraisal of an Old Concept
Anti-Cancer Agents in Medicinal Chemistry Meet the Editorial Board:
Anti-Cancer Agents in Medicinal Chemistry Para-Nonylphenol Induces Apoptosis of U937 Human Monocyte Leukemia Cells in vitro
Endocrine, Metabolic & Immune Disorders - Drug Targets Hyperpolarized 13Carbon MR
Current Pharmaceutical Biotechnology